---
schema_version: "secwatch.filing_event.v1"
accession: "0000879407-25-000004"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2025-09-02T23:59:59+00:00"
generated_at: "2026-05-17T09:07:24.755224+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arrowhead licenses ARO-SNCA to Novartis for $200M upfront, up to $2B milestones

## Summary
- Arrowhead receives $200M upfront; eligible for up to $2B in development, regulatory, sales milestones.
- Novartis gets exclusive worldwide license to preclinical ARO-SNCA (siRNA for synucleinopathies like Parkinson's).
- Arrowhead will complete preclinical work; Novartis handles clinical development, manufacturing, commercialization.
- Arrowhead eligible for tiered royalties up to low double digits on net product sales.
- Transaction expected to close H2 2025, subject to HSR antitrust clearance and customary conditions.

## SEC filing metadata
- accession: 0000879407-25-000004
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2025-09-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000087940725000004/0000879407-25-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000087940725000004/arwr-20250902.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000879407-25-000004
- JSON: https://secwatch.observer/filing/0000879407-25-000004.json
- Plain text: https://secwatch.observer/filing/0000879407-25-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.